Head-To-Head Analysis: Standard BioTools (NASDAQ:LAB) & Zhongchao (NASDAQ:ZCMD)

Zhongchao (NASDAQ:ZCMD) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zhongchao and Standard BioTools, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhongchao	1	0	0	0	1.00
Standard BioTools	1	2	0	0	1.67

Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 45.36%. Given Standard BioTools’ stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Zhongchao.

Volatility and Risk

Zhongchao has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Institutional & Insider Ownership

1.7% of Zhongchao shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 28.6% of Zhongchao shares are owned by insiders. Comparatively, 23.2% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Zhongchao and Standard BioTools’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zhongchao	N/A	N/A	N/A
Standard BioTools	-59.39%	-11.21%	-8.51%

Valuation & Earnings

This table compares Zhongchao and Standard BioTools”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhongchao	$11.38 million	0.73	-$6.31 million	N/A	N/A
Standard BioTools	$85.33 million	4.25	-$74.90 million	($0.20)	-4.64

Zhongchao has higher earnings, but lower revenue than Standard BioTools.

Summary

Standard BioTools beats Zhongchao on 6 of the 11 factors compared between the two stocks.

About Zhongchao

Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.